
Reset all filters
01 6Equa/EquMet
02 6Galvus
03 5Galvus Group
04 2Glumetza
05 5Janumet
06 3Trajenta/ Jentadueto
07 2Trajenta/Jentadueto
Vildagliptin, Metformin Hydrochloride
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 1,801
2019 Revenue in Millions : 1,857
Growth (%) : -3
Vildagliptin, Metformin Hydrochloride
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 391
2019 Revenue in Millions : 75
Growth (%) : 421
Vildagliptin, Metformin Hydrochloride
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 1,971
2019 Revenue in Millions : 2,041
Growth (%) : -3
Vildagliptin, Metformin Hydrochloride
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 1,709
2020 Revenue in Millions : 1,801
Growth (%) : 3
Vildagliptin, Metformin Hydrochloride
Main Therapeutic Indication : Diabetes
Currency : USD
2020 Revenue in Millions : 1,199
2019 Revenue in Millions : 1,297
Growth (%) : -8
Vildagliptin, Metformin Hydrochloride
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 322
2020 Revenue in Millions : 391
Growth (%) : -6
Vildagliptin, Metformin Hydrochloride
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 1,092
2020 Revenue in Millions : 1,199
Growth (%) : -9
Vildagliptin, Metformin Hydrochloride
Main Therapeutic Indication : Diabetes
Currency : USD
2021 Revenue in Millions : 1,964
2020 Revenue in Millions : 1,971
Growth (%) : 0
Vildagliptin, Metformin Hydrochloride
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 1,846
2021 Revenue in Millions : 1,709
Growth (%) : 8
Vildagliptin, Metformin Hydrochloride
Main Therapeutic Indication : Diabetes
Currency : USD
2022 Revenue in Millions : 1,700
2021 Revenue in Millions : 1,964
Growth (%) : -13